On the additional risk of delisting of ordinary shares of BioXcel Therapeutics, Inc. (BTAI)

The International Trading System Limited (hereinafter — ITS) hereby informs on the information concerning delisting risk of ordinary shares of BioXcel Therapeutics, Inc. (ISIN US09075P1057, hereinafter — Shares) from The Nasdaq Stock Market LLC (hereinafter — Nasdaq).

Information on delisting risk of ordinary shares by Nasdaq

On November 14, 2024 BioXcel Therapeutics, Inc. (hereinafter – the Company) submitted Quarterly report on Form 10-Q to The United States Securities and Exchange Commission (hereinafter – SEC). According to the report, the Company experiences a history of significant losses, negative cash flows from operations, potential increased obligations and funding requirement under Credit Agreement, limited liquidity resources and dependence on ability to obtain additional financing to fund operations. These conditions led the Company’s management to raise substantial doubt about its ability to continue as a going concern for more than twelve months from the date of these financial statements. For more information, please refer to the report available on the SEC website.

On September 16, 2024 the Company already received a notice from Nasdaq indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the minimum bid price of the Company’s common stock had been below $1.00 per share for the last 30 consecutive business days.

Information regarding possible actions to be taken by ITS Ltd.

ITS Ltd. conducts regular monitoring of the relevant information disclosed by the Company. Delisting of the Company’s securities by Nasdaq will be considered to constitute a breach of the ITS Regulations on admitting financial instruments to trading and result in termination of trading in the Qualified Investments on ITS.